Using alteplase to improve fluid drainage and breathlessness in patients with malignant pleural effusion
Official title: A Randomized Trial of Alteplase Versus Placebo Through an Indwelling Pleural Catheter for Management of Symptomatic Septated MPE
Run by M.D. Anderson Cancer Center · NCT06184321 · Data updated 2026-11-12
This study tests if the medication alteplase can help people with fluid buildup in the lungs feel better and breathe easier when regular drainage isn’t enough.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 2 sites (Baltimore, Maryland and 1 other locations) |
| Status | Recruiting |
| Started | August 17, 2023 |
| Main results expected | February 2, 2027 |
| Study ends | February 2, 2027 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT06184321 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with symptomatic septated malignant pleural effusion who are unable to drain fluid adequately through an indwelling pleural catheter.
✕Probably not a fit
Patients who cannot provide informed consent or have a blocked indwelling pleural catheter may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of alteplase, a medication that dissolves blood clots, in improving pleural fluid drainage and alleviating dyspnea in patients with symptomatic septated malignant pleural effusion who are unable to fully drain fluid through an indwelling pleural catheter. Participants are randomized into two groups: one receiving alteplase and the other receiving a placebo, with assessments of dyspnea conducted using the Borg score and visual analog scale at one week. The study aims to determine if alteplase can enhance symptom management in this patient population.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from breathlessness due to malignant pleural effusion.
How similar studies have gone: While the use of alteplase in this specific context is novel, similar approaches in other settings have shown promise in improving fluid drainage and symptom relief.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Referral to pulmonary services for inability to drain fully via IPC * Presence of a symptomatic septated pleural effusion * A pleural effusion of significant moderate to large volume based on: * Chest radiograph: effusion filling \>= 1/3 of the hemithorax, or * Computed tomography (CT)-scan: AP depth of the effusion \>= 1/3 of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung surrounded by effusion, or * Ultrasound: effusion spanning at least three intercostal spaces, with a \>= 3 cm in at least one intercostal space, while the patient sits upright * Age \> 18 * Borg score \>= 3 * Absence of a blocked IPC as demonstrated by a flush with 20 cc of saline x1 without resistance * Presence of septated effusion based on ultrasound (US) and chest CT Exclusion Criteria: * Inability to provide informed consent * Study subject has any disease or condition that interferes with safe completion of the study including: * Uncorrectable coagulopathy based on criteria followed by cardiopulmonary center for procedures. * Active bleeding * Known allergic reaction to thrombolytics * Pleural effusion is smaller than expected on bedside pre-procedure ultrasound * No septations and/or no loculations on bedside pre-procedure ultrasound * Patient is asymptomatic * Blocked IPC as determined by saline flush
Where it's running
-
M D Anderson Cancer Center
Houston, Texas, United States Recruiting -
John Hopkins University
Baltimore, Maryland, United States Not yet recruiting
Study contacts
- Principal investigator: Horiana Grosu, M D — M.D. Anderson Cancer Center
- Study coordinator: Horiana Grosu, M D
- Email: hbgrosu@mdanderson.org
- Phone: 713-792-6238
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Video education to boost knowledge and interest in cancer clinical trials
Adults in the Detroit area will watch a short educational video to see if it increases their knowledge about and interest in cancer clinical trials.
-
Using weighted blankets to reduce anxiety in cancer patients during infusions
This study is testing whether using weighted blankets can help reduce anxiety in cancer patients during their first infusion therapy.
-
Letermovir to prevent cytomegalovirus after pediatric stem cell transplant
This study will try giving letermovir to CMV-positive children and adolescents receiving allogeneic stem cell transplants to see if it lowers CMV infections after transplant compared with the expected rate without prophylaxis.
-
Collecting blood and tissue samples for HIV/AIDS-related cancer research
This study is collecting blood and tissue samples from people living with HIV and related cancers to help researchers learn more about how HIV affects cancer development.
-
Collecting blood samples to evaluate tests for early cancer detection
This study is collecting blood and tissue samples from people with and without cancer to see if new tests can help detect cancer earlier.
-
Combining vertebroplasty and radiation therapy for spine cancer patients
This study is testing whether combining a special type of radiation therapy with a procedure to strengthen the spine can help people with tough-to-treat cancer in that area feel better and live longer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.